TY - JOUR
T1 - Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
AU - Duijnhoven, Ruben G.
AU - Straus, Sabine M.J.M.
AU - Souverein, Patrick C.
AU - de Boer, Anthonius
AU - Bosch, J. L.H.Ruud
AU - Hoes, Arno W.
AU - De Bruin, Marie L.
N1 - Funding Information: Acknowledgments The division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University has received unrestricted funding from the Medicines Evaluation Board (MEB) for the submitted work under the Regulatory Science collaboration between the MEB and Utrecht University. The funder had no role in the design of the study; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. Publisher Copyright: © 2014, Springer International Publishing Switzerland.
PY - 2014/10/31
Y1 - 2014/10/31
N2 - Methods: A case–control study was conducted with data from the United Kingdom Clinical Practice Research Datalink database among all men aged 45 years and older in the period 1 January 1992 to 31 December 2011. Cases of men diagnosed with breast cancer were matched to up 10 controls on age and general practice. Crude and adjusted odds ratios were estimated for the risk of breast cancer associated with the use of 5-ARIs.Results: Three hundred and ninety-eight cases were identified and matched to 3,930 controls. Ever use of 5-ARIs was associated with an adjusted odds ratio for breast cancer of 1.08 (95 % CI 0.62–1.87) compared to non-users. Increasing cumulative duration of treatment showed no increasing risks: adjusted odds ratios for use for less than 280, for 280 to 1,036 and for more than 1,036 days were 1.21 (95 % CI 0.47–3.10), 0.94 (95 % CI 0.36–2.41) and 1.29 (95 % CI 0.54–3.08), respectively.Conclusions: In this study, there was no evidence of an association between short- or long-term treatment with 5-ARIs and the risk for breast cancer in older men.Background: The 5α-reductase inhibitors (5-ARI) finasteride and dutasteride are indicated for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia. Case reports have suggested that 5-ARIs increase the risk for male breast cancer, with no conclusive evidence. The objective of this study was to quantify the association between use of 5-ARIs and the risk for male breast cancer.
AB - Methods: A case–control study was conducted with data from the United Kingdom Clinical Practice Research Datalink database among all men aged 45 years and older in the period 1 January 1992 to 31 December 2011. Cases of men diagnosed with breast cancer were matched to up 10 controls on age and general practice. Crude and adjusted odds ratios were estimated for the risk of breast cancer associated with the use of 5-ARIs.Results: Three hundred and ninety-eight cases were identified and matched to 3,930 controls. Ever use of 5-ARIs was associated with an adjusted odds ratio for breast cancer of 1.08 (95 % CI 0.62–1.87) compared to non-users. Increasing cumulative duration of treatment showed no increasing risks: adjusted odds ratios for use for less than 280, for 280 to 1,036 and for more than 1,036 days were 1.21 (95 % CI 0.47–3.10), 0.94 (95 % CI 0.36–2.41) and 1.29 (95 % CI 0.54–3.08), respectively.Conclusions: In this study, there was no evidence of an association between short- or long-term treatment with 5-ARIs and the risk for breast cancer in older men.Background: The 5α-reductase inhibitors (5-ARI) finasteride and dutasteride are indicated for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia. Case reports have suggested that 5-ARIs increase the risk for male breast cancer, with no conclusive evidence. The objective of this study was to quantify the association between use of 5-ARIs and the risk for male breast cancer.
KW - 5-α Reductase inhibitors
KW - Adverse effects
KW - Benign prostatic hyperplasia
KW - Dutasteride
KW - Epidemiology
KW - Finasteride
KW - Male breast cancer
UR - http://www.scopus.com/inward/record.url?scp=84911959420&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s10552-014-0455-6
DO - https://doi.org/10.1007/s10552-014-0455-6
M3 - Article
C2 - 25135615
SN - 0957-5243
VL - 25
SP - 1577
EP - 1582
JO - Cancer Causes and Control
JF - Cancer Causes and Control
IS - 11
ER -